Outlook Therapeutics, Inc. OTLK used its fiscal third-quarter 2026 call to shift attention from approval to commercialization, detailing LYTENAVA's U.S. launch plan after FDA approval for wet AMD.
President and chief executive officer (CEO) Robert Jahr said management expects a U.S. launch before year-end 2026, centering on reimbursement, pricing, supply and retina-practice engagement. The call also introduced first-year revenue guidance and clarified the 2030 sales objective.
OTLK Turns to a Year-End U.S. Launch
Robert Jahr said the U.S. anti-VEGF retina market is about $8.5 billion, with 3.6 million off-label repackaged bevacizumab injections in 2025, including 2.2 million for wet AMD.
Jahr positioned LYTENAVA as an FDA-approved ophthalmic bevacizumab option alongside branded drugs, biosimilars and repackaged bevacizumab. He said management's base-case objective is more than $500 million in annual U.S. sales by 2030.
The CEO added that OTLK has sufficient supply for launch later in 2026 and is prioritizing high-volume practices with significant bevacizumab use.
Outlook Sets a Progressive Revenue Ramp
Adjusted net loss was $0.09 per share, in line with the Zacks Consensus Estimate. Revenues of $9,000 missed the consensus estimate by 99.25%.
Executive vice president and chief financial officer Lawrence Kenyon guided $50 million to $75 million of net revenues in the first 12 months after the U.S. launch, with Europe contributing approximately 10% to 15%. Approximately 10% is expected in the first three months and approximately 50% in the fourth quarter.
Kenyon tied the acceleration to an anticipated permanent J-code in April 2027. He expects quarterly SG&A to approximately double by year-end 2026, followed by an approximately 10% increase during 2027, while R&D remains relatively steady over the next 12 months.
OTLK Builds Around Access and Reimbursement
Jahr said LYTENAVA's wholesale acquisition cost is expected to be below $500 per vial, with pricing designed around patient affordability, payer access and buy-and-bill economics.
OTLK plans approximately 30 customer-facing commercial hires and approximately 20 field reimbursement personnel. Jahr said practices need workable product access, coding and reimbursement alongside physician awareness.
The company plans to apply for a permanent HCPCS code by Oct. 1, 2026. Jahr said launch pace will also reflect payer engagement, supply readiness and customer feedback.
Outlook Q&A Tests the $500 Million Case
A BTIG analyst asked about upside if compounded bevacizumab availability is disrupted. Jahr said that scenario could add just under $300 million to the 2030 opportunity, while displaced volume could also move to biosimilars.
Jahr also said just under 800 retina physicians, one-third of the target universe, represent slightly less than half of the $500 million 2030 opportunity and are potential early adopters once reimbursement is established.
A Brookline Capital Markets analyst asked about biosimilar competition. Jahr said the model assumes compounded bevacizumab remains available, biosimilars arrive on time with continued pricing pressure, and other modalities enter as expected. He characterized the assumptions as conservative.
OTLK Funds Launch and Keeps Europe Selective
Kenyon said OTLK had $11.2 million in cash at June 30. A subsequent public offering was expected to generate approximately $51.1 million in net proceeds for the U.S. launch and working capital.
Kenyon said European unit sales rose 46% from the fiscal second quarter. Jahr said Outlook has reset European costs and will expand selectively amid pricing pressure, tenders and market-specific barriers.
The Netherlands is targeted for early 2027, while partner Mediconsult is preparing a 2027 Switzerland launch. Jahr said Europe could be less than one-quarter of the U.S. opportunity by 2030, with the U.S. at 90% or more of the total commercial opportunity in net revenue terms.
Outlook's Focus Shifts to Commercial Execution
Jahr closed with priorities around payer access, field-force buildout, supply, medical affairs and account engagement.
Kenyon's spending outlook points to a higher commercialization cost base ahead of the revenue ramp. Management's plan centers on launching in late 2026 and broadening adoption as reimbursement infrastructure matures.
Zacks Rank and Style Scores
OTLK carries a Zacks Rank #3 (Hold). Its Growth Score and Momentum Score are A, while the Value Score is F and the VGM Score is C, reflecting a mixed Style Score profile.
The Style Score framework favors stronger grades, especially with Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks. OTLK's A grades in growth and momentum are favorable, but its F Value Score and C VGM Score temper the overall signal. The Zacks Rank can change as analyst estimates are revised after the reported results.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Outlook Therapeutics, Inc. (OTLK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
